NASDAQ:SRRK - Nasdaq - US80706P1030 - Common Stock - Currency: USD
39.15
+1.14 (+3%)
The current stock price of SRRK is 39.15 USD. In the past month the price decreased by -16.22%. In the past year, price increased by 150.96%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.85 | 354.98B | ||
AMGN | AMGEN INC | 15.03 | 159.99B | ||
GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
NTRA | NATERA INC | N/A | 22.20B | ||
BIIB | BIOGEN INC | 8.32 | 19.98B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2018-05-24. The firm is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.
SCHOLAR ROCK HOLDING CORP
301 Binney Street, 3rd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Stuart A. Kingsley
Employees: 150
Company Website: https://scholarrock.com/
Investor Relations: https://investors.scholarrock.com/
Phone: 18572593860
The current stock price of SRRK is 39.15 USD. The price increased by 3% in the last trading session.
The exchange symbol of SCHOLAR ROCK HOLDING CORP is SRRK and it is listed on the Nasdaq exchange.
SRRK stock is listed on the Nasdaq exchange.
15 analysts have analysed SRRK and the average price target is 46.63 USD. This implies a price increase of 19.1% is expected in the next year compared to the current price of 39.15. Check the SCHOLAR ROCK HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SCHOLAR ROCK HOLDING CORP (SRRK) has a market capitalization of 3.66B USD. This makes SRRK a Mid Cap stock.
SCHOLAR ROCK HOLDING CORP (SRRK) currently has 150 employees.
SCHOLAR ROCK HOLDING CORP (SRRK) has a support level at 37.06 and a resistance level at 45.48. Check the full technical report for a detailed analysis of SRRK support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SRRK does not pay a dividend.
SCHOLAR ROCK HOLDING CORP (SRRK) will report earnings on 2025-02-27, after the market close.
SCHOLAR ROCK HOLDING CORP (SRRK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.35).
The outstanding short interest for SCHOLAR ROCK HOLDING CORP (SRRK) is 17% of its float. Check the ownership tab for more information on the SRRK short interest.
ChartMill assigns a technical rating of 4 / 10 to SRRK. When comparing the yearly performance of all stocks, SRRK is one of the better performing stocks in the market, outperforming 96.81% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to SRRK. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SRRK reported a non-GAAP Earnings per Share(EPS) of -2.35. The EPS decreased by -20.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -89.85% | ||
ROE | -152.56% | ||
Debt/Equity | 0.37 |
ChartMill assigns a Buy % Consensus number of 85% to SRRK. The Buy consensus is the average rating of analysts ratings from 15 analysts.